Acute Myeloid Leukemia Clinical Trials

162 studies are recruiting for acute myeloid leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

   This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow…

   Stage

   Phase 1

   Ages

   1 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT03630991 on ClinicalTrials.gov

2. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   186 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554393 on ClinicalTrials.gov

3. Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   226 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554406 on ClinicalTrials.gov

4. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   349 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

5. A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

   To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Johns Hopkins University, Baltimore, Maryland

   Locations

   4 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06284486 on ClinicalTrials.gov

6. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   227 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06317649 on ClinicalTrials.gov

7. Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Banner University Medical Center - Tucson, Tucson, Arizona

   Locations

   136 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06672146 on ClinicalTrials.gov

8. Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

   The goal of this all-oral combination is to deliver safe and effective therapy for the largest portion of AML subtypes (NPM1mt, KMT2Ar, NUP98r ~ 40-45%).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06769490 on ClinicalTrials.gov

9. Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

   This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT04282187 on ClinicalTrials.gov

10. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

    This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

    Stage

    Phase 3

    Ages

    0 to 21

    Site

    Children's Hospital of Alabama, Birmingham, Alabama

    Locations

    206 in total

    Run by

    Children's Oncology Group

    See if you can join NCT04293562 on ClinicalTrials.gov

11. A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

    This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy …

    Stage

    Phase 2

    Ages

    0 to 21

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Locations

    10 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT05955261 on ClinicalTrials.gov

12. Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

    This clinical trial studies whether less fit adults with acute myeloid leukemia (AML) or myeloid neoplasms are willing to let a computer program decide (randomization) whether they receive lower- or higher-intensity chemotherapy. Historically, treatment decision-making for patients with AML or myel…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT07094750 on ClinicalTrials.gov

13. FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

    This phase I trial tests the safety, side effects and best dose of FH-WT1-E50 TCR T cells with azacitidine for the treatment of minimal residual disease (MRD) positive acute myeloid leukemia (AML). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT07645469 on ClinicalTrials.gov

14. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

    Stage

    Phase 1

    Ages

    0 and older

    Site

    University of Colorado, Aurora, Colorado

    Locations

    57 in total

    Run by

    Syndax Pharmaceuticals

    See if you can join NCT04065399 on ClinicalTrials.gov

15. Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

    This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling mutated AML. Venetoclax is in a class of medications called B-cell lym…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

    Locations

    2 in total

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06504459 on ClinicalTrials.gov

16. Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

    This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not r…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Weill Cornell, New York, New York

    Locations

    64 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06824168 on ClinicalTrials.gov

17. A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

    This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy. Primary objective: - To estimate the rate of bacterial bloodstream infection in pedi…

    Stage

    Phase 1

    Ages

    Up to 25

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT06810583 on ClinicalTrials.gov

18. A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

    Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope National Medical Center /ID# 279568, Duarte, California

    Locations

    28 in total

    Run by

    AbbVie

    See if you can join NCT07581002 on ClinicalTrials.gov

19. Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

    This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocki…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    4 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT03471260 on ClinicalTrials.gov

20. A Study of BGB-11417 in Participants With Myeloid Malignancies

    The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Tampa General Hospital, Tampa, Florida

    Locations

    47 in total

    Run by

    BeOne Medicines

    See if you can join NCT04771130 on ClinicalTrials.gov

21. A Telehealth Advance Care Planning Intervention

    The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare pr…

    Stage

    Not phased

    Ages

    60 and older

    Site

    University of Rochester, Rochester, New York

    Run by

    University of Rochester

    See if you can join NCT05875805 on ClinicalTrials.gov

22. A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

    A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    2 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06616636 on ClinicalTrials.gov

23. A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

    The primary purpose of Phase 1 is to characterize the safety and tolerability to identify the recommended dose (RD) of Debio 1562M for further development. The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Comprehensive Cancer Center, Duarte, California

    Locations

    7 in total

    Run by

    Debiopharm International SA

    See if you can join NCT06969430 on ClinicalTrials.gov

24. A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

    This clinical trial studies how well a home-based exercise intervention called Cardiorespiratory Fitness in Bone Marrow Transplant Program (CAREFit-BMT) works in improving heart function among patients with high risk acute myeloid leukemia (AML) undergoing stem cell transplant. Older adults and tho…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT07616921 on ClinicalTrials.gov

25. A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or ref…

    Stage

    Phase 1

    Ages

    0 to 17

    Site

    Lucile Packard Children's Hospital /ID# 276015, Palo Alto, California

    Locations

    13 in total

    Run by

    AbbVie

    See if you can join NCT07306832 on ClinicalTrials.gov